Pfizer USA

Senior Director- Asset Lead Biosimilars Research Development Unit

Daniel Alvarez, M.D. Senior Director. At Pfizer Inc. is currently a Development Asset Lead in the biosimilar program at Pfizer and has worked in the biosimilar space since 2012. Daniel joined the pharmaceutical industry in 2005, and held previously positions of increasing responsibility at Schering Plough and Wyeth. He has worked in Ph1-4 clinical trials in development in the areas of HIV, Hepatitis C, Psoriasis, Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis and opioid induced constipation. He has participated as the medical expert in regulatory with Enbrel in the EU and Japan. Daniel serves in the Immunosafety Council, the Pfizer Hepatic Injury Council and is member of the Hepatic Injury Advisory Panel. He is one of the Pfizer representatives in the Translational Team and previously also in the Hepatotoxicity Working Group, both part of the Predictive Testing Safety Consortium under the umbrella of the C-PATH Institute in collaboration with the FDA. He also was the Pfizer clinical representative in the PML consortium.